High-intensity statins after stroke tracked slightly less dementia across 206,416 survivors

Ask people what statins do to the brain and a good number will say they fog it. The belief has outlived several attempts to test it, and it is one of the commoner reasons people quietly stop taking a drug prescribed to keep them alive.

Stroke survivors are a useful place to look, because stroke survivors face elevated risks of cognitive decline and dementia anyway, and because after a stroke almost everybody is put on a statin. The only question is how strong a dose.

Writing in the Journal of Stroke and Cerebrovascular Diseases, researchers compared the two across 206,416 matched patients drawn from 104 U.S. healthcare organizations. Over five years, the group on the stronger dose developed slightly less dementia, not more.

What statins are being accused of

Statins are the most common medicines used to treat high cholesterol. They work by slowing down how much cholesterol the liver makes and helping the liver clear what is already circulating.

The brain, meanwhile, is an organ built substantially of fat and dependent on cholesterol for the membranes of its cells. That is the intuition behind the worry: a drug that lowers cholesterol everywhere might be starving neurons of a material they need.

It is a reasonable thing to suspect and it has been hard to shake, partly because memory complaints are common in exactly the age group that gets prescribed statins, so anyone looking for a connection will find one in their own life.

Why this comparison is unusually clean

Most attempts to answer the question compare people on statins with people not on them, and immediately run into the difference between the two: someone prescribed a statin has a reason to be on one.

This study sidesteps that. Everyone in it had a stroke, and everyone received a statin within 7 days. The comparison is between doses, not between treated and untreated, so the two groups share the event that put them there and share the decision to treat it.

Previously, evidence on whether pushing the dose higher does anything to the brain, beyond vascular risk reduction, remains uncertain. That gap is what this fills.

What five years showed

Dementia appeared in 6.6% of the high-intensity group and 6.9% of the low or moderate group. In counted people, that is 6,816 diagnoses against 7,104.

The difference is three people in every thousand over five years. A comparison of 206,416 patients can pick up a difference that small with confidence, and picking it up is not the same as it mattering to anyone.

Deaths from any cause were lower on the stronger dose as well, by a similar slim margin, which is at least consistent with the established reason for prescribing it.

The pattern that runs backwards

Here the study becomes more interesting than its headline.

If statins protect the brain, the mechanism is vascular. They keep arteries clearer, which should show up as fewer of the small strokes and reduced blood flow that cause vascular dementia. That is the prediction.

The data did the opposite. High-intensity therapy was associated with lower risk of AD, meaning Alzheimer’s disease, by around 12%. For vascular dementia, there was no significant difference, and the estimate leaned very slightly the other way.

Alzheimer’s is the form with the least obvious vascular route and it moved; the form built out of blood vessel damage did not. Either something is happening that nobody has a mechanism for, or the split is an artifact of how dementia gets coded in medical records, where a specific Alzheimer’s diagnosis and a general one are often a matter of which specialist saw the patient.

The second explanation is duller and more likely.

What a records study cannot settle

Doctors chose these doses, and they had reasons.

A patient who is frail, elderly, on a long list of other medicines, or has a liver that is already struggling is more likely to be started on the gentler option. Every one of those characteristics also predicts dementia. Matching on 24 recorded variables narrows the gap; it cannot capture the clinical judgment that produced the prescription in the first place.

There is also the question of what a dementia diagnosis in a database represents. It records the moment a doctor wrote a code, which depends on the patient having attended, complained, and been referred. People who take the stronger statin are, on average, people in closer contact with the medical system, and closer contact cuts both ways for whether a diagnosis gets recorded at all.

The authors put the appropriate weight on it themselves: this was an association across five years, and randomized evidence is what would settle it.

What it is worth knowing

Not as a reason to change a dose. That decision turns on preventing a second stroke, which this analysis did not measure.

Its value is narrower and, for a lot of people, more useful. Someone who has had a stroke, been handed a high-dose statin, and half-remembers reading that these drugs cloud your thinking now has a large, well-matched comparison pointing the other way. Whatever else the stronger dose does over five years, it did not leave people with more dementia than the weaker one.

That is a modest thing to be able to say. It is also the thing the worry actually needed answering.